Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study

Abstract Papillary craniopharyngiomas are characterized by the BRAF V600E mutation. Enhancement of glucose metabolism may be involved in the downstream of the BRAF V600E mutation in many types of tumors. Glucose metabolism was investigated in craniopharyngioma using immunohistochemical analysis. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naoto Mukada, Masahiko Tosaka, Nozomi Matsumura, Rei Yamaguchi, Masanori Aihara, Koji Isoda, Tetsuya Higuchi, Yoshito Tsushima, Hideaki Yokoo, Yuhei Yoshimoto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/43a680b71c9742d4894ca14f18f211fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43a680b71c9742d4894ca14f18f211fe
record_format	dspace
spelling	oai:doaj.org-article:43a680b71c9742d4894ca14f18f211fe2021-12-02T15:13:14ZSubtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study10.1038/s41598-020-80259-42045-2322https://doaj.org/article/43a680b71c9742d4894ca14f18f211fe2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80259-4https://doaj.org/toc/2045-2322Abstract Papillary craniopharyngiomas are characterized by the BRAF V600E mutation. Enhancement of glucose metabolism may be involved in the downstream of the BRAF V600E mutation in many types of tumors. Glucose metabolism was investigated in craniopharyngioma using immunohistochemical analysis. The study included 29 cases of craniopharyngioma (18 adamantinomatous type [ACP], 11 papillary type [PCP]). Immunohistochemical analysis was performed with anti-glucose transporter-1 (GLUT-1), anti-hexokinase-II (HK-II), anti-BRAF V600E, and anti-beta-catenin antibodies. Expressions of GLUT-1 and HK-II were evaluated using a semiquantitative 4-tiered scale as 0, 1+, 2+, 3+, and divided into negative (0 or 1+) or positive (2+ or 3+) group. GLUT-1 expression level was significantly higher in PCPs than ACPs (0, 1+, 2+, 3+ = 2, 12, 4, 0 cases in ACP, respectively, 0, 1+, 2+, 3+ = 0, 2, 5, 4 in PCP, p = 0.001), and most PCPs were classified into positive group (positive rate, 22.2% [4/18] in ACP, 81.8% [9/11] in PCP; p = 0.003). HK-II expression was also conspicuous in PCPs (0, 1+, 2+, 3+ = 7, 9, 2, 0 cases in ACP, 0, 3, 3, 5 in PCP; p = 0.001), and most of them divided into positive group (positive rate, 11.1% [2/18] in ACP, 72.7% [8/11] in PCP; p = 0.001). Expression patterns of BRAF V600E and beta-catenin reflected the clinicopathological subtypes. Both GLUT-1 and HK-II expressions were prominent in PCP. Glucose metabolism might be more enhanced in PCP than ACP. PCP may use the glucose metabolic system downstream of the BRAF V600E mutant protein.Naoto MukadaMasahiko TosakaNozomi MatsumuraRei YamaguchiMasanori AiharaKoji IsodaTetsuya HiguchiYoshito TsushimaHideaki YokooYuhei YoshimotoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Naoto Mukada Masahiko Tosaka Nozomi Matsumura Rei Yamaguchi Masanori Aihara Koji Isoda Tetsuya Higuchi Yoshito Tsushima Hideaki Yokoo Yuhei Yoshimoto Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
description	Abstract Papillary craniopharyngiomas are characterized by the BRAF V600E mutation. Enhancement of glucose metabolism may be involved in the downstream of the BRAF V600E mutation in many types of tumors. Glucose metabolism was investigated in craniopharyngioma using immunohistochemical analysis. The study included 29 cases of craniopharyngioma (18 adamantinomatous type [ACP], 11 papillary type [PCP]). Immunohistochemical analysis was performed with anti-glucose transporter-1 (GLUT-1), anti-hexokinase-II (HK-II), anti-BRAF V600E, and anti-beta-catenin antibodies. Expressions of GLUT-1 and HK-II were evaluated using a semiquantitative 4-tiered scale as 0, 1+, 2+, 3+, and divided into negative (0 or 1+) or positive (2+ or 3+) group. GLUT-1 expression level was significantly higher in PCPs than ACPs (0, 1+, 2+, 3+ = 2, 12, 4, 0 cases in ACP, respectively, 0, 1+, 2+, 3+ = 0, 2, 5, 4 in PCP, p = 0.001), and most PCPs were classified into positive group (positive rate, 22.2% [4/18] in ACP, 81.8% [9/11] in PCP; p = 0.003). HK-II expression was also conspicuous in PCPs (0, 1+, 2+, 3+ = 7, 9, 2, 0 cases in ACP, 0, 3, 3, 5 in PCP; p = 0.001), and most of them divided into positive group (positive rate, 11.1% [2/18] in ACP, 72.7% [8/11] in PCP; p = 0.001). Expression patterns of BRAF V600E and beta-catenin reflected the clinicopathological subtypes. Both GLUT-1 and HK-II expressions were prominent in PCP. Glucose metabolism might be more enhanced in PCP than ACP. PCP may use the glucose metabolic system downstream of the BRAF V600E mutant protein.
format	article
author	Naoto Mukada Masahiko Tosaka Nozomi Matsumura Rei Yamaguchi Masanori Aihara Koji Isoda Tetsuya Higuchi Yoshito Tsushima Hideaki Yokoo Yuhei Yoshimoto
author_facet	Naoto Mukada Masahiko Tosaka Nozomi Matsumura Rei Yamaguchi Masanori Aihara Koji Isoda Tetsuya Higuchi Yoshito Tsushima Hideaki Yokoo Yuhei Yoshimoto
author_sort	Naoto Mukada
title	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
title_short	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
title_full	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
title_fullStr	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
title_full_unstemmed	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study
title_sort	subtype-dependent difference of glucose transporter 1 and hexokinase ii expression in craniopharyngioma: an immunohistochemical study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/43a680b71c9742d4894ca14f18f211fe
work_keys_str_mv	AT naotomukada subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT masahikotosaka subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT nozomimatsumura subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT reiyamaguchi subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT masanoriaihara subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT kojiisoda subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT tetsuyahiguchi subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT yoshitotsushima subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT hideakiyokoo subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy AT yuheiyoshimoto subtypedependentdifferenceofglucosetransporter1andhexokinaseiiexpressionincraniopharyngiomaanimmunohistochemicalstudy
_version_	1718387564721733632

Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study

Ejemplares similares